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ABSTRACT 
Mycoplasma hyopneumoniae causes a chronic respiratory disease in swine. It is an 
important component of the porcine respiratory disease complex and has been shown to 
enhance disease due to other pathogens. Few definitive studies of the surface architecture of 
M. hyopneumoniae have been reported although mycoplasmas in general abound with 
antigenic surface lipoproteins and other structures that contribute to disease. Hindering 
studies in M hyopneumoniae are the inability to grow the organism on agar surfaces and to 
genetically manipulate the organism. Some monoclonal antibodies are available, but they have 
not been fully characterized to identify the gene product recognized. To further study the 
surface proteins of M hyopneumoniae it was necessary to raise polyclonal antibodies against 
specific gene products. This approach was difficult because mycoplasma gene sequences 
contain TGA codons, usually a stop codon, that code for tryptophan. Also, mycoplasma 
gene sequences express poorly in Escherichia coli, the normal expression host. With the 
completion of the M hyopneumoniae genome sequence, the entire repertoire of lipoprotein 
genes was now available. A DNA vaccine approach was chosen to induce monospecific, 
polyclonal antisera in rabbits. Putative open reading frames from M hyopneumoniae were 
cloned successively into pCR2.1 and then into the expression vector pSTBO78 after being 
corrected for TGA codon usage. The expression vector constructs were then used to 
vaccinate rabbits in an effort to raise polyclonal antibodies against the encoded gene. Rabbit 
serum was tested by immunoblot and immunofluorescence to verify the presence of 
antibodies against the protein encoded by the DNA vaccine. Results showed positive results 
in twenty-eight of the thirty-four of the ORFs used for vaccination. Immunoblots showed 
protein products of the expected size in eighteen ORFs and only smaller cleaved products in 
four. Three ORFs showed regular banding patterns of smaller protein products, alluding to a 
mechanism of size variation in the final protein. Immunofluorescence gave positive results 
that reflected surface proteins available to the host during infection for antibody recognition. 
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INTRODUCTION AND LITERATURE REVIEW 
Biology 
Organisms included in the taxonomic class Mollicutes (generically referred to as 
mycoplasmas) are separated from other bacteria primarily on the basis of their lack of a cell 
wall. They are the smallest free self-replicating organisms known. With genomes ranging from 
580 kilobases to 2200 kb (57), they have been used as models to study the minimal 
components necessary for life (30), referred to as the Minimal Cell Concept (61). 
Mycoplasmas are found in every country and most species are distributed throughout the 
world, though some species are localized (57). An example of this would be M. mycoides 
subsp. mycoides small colony (SC), which is extant in Africa and a small part of Asia. Over 
two hundred members of this class have been isolated from a variety of hosts such as reptiles, 
fish, arthropods, plants, and mammals including humans (36). Mycoplasmas infecting 
mammalian systems show tissue specificity for the host and generally infect mucous 
membranes of respiratory and urogenital tracts, eyes, mammary glands, joints and rumen. 
Host infection by mycoplasmas are often commensal, but can take the form a deleterious 
disease. Disease caused by mycoplasmas are generally diseases of the mucosal surfaces and 
joints, such as pneumonia, conjunctivitis and arthritis (72). 
Enzootic Pneumonia 
Of the three mycoplasmas known to cause disease in swine, Mycoplasma hyopneumoniae 
causes the most acute and detrimental disease, often referred to as Enzootic Pneumonia. The 
disease most commonly affects swine six weeks to one year old, manifesting with a chronic, 
non-productive cough, slow weight gain, lowered feed utilization and a low incidence of 
mortality. These factors make the disease a significant concern to the swine producing 
industry, due to lost profits from sick, slow-growing pigs that weigh less at market than pigs 
never infected with M hyopneumoniae (78). M. hyopneumoniae infection is widespread and 
endemic to most herds throughout the world. The bacterium is spread easily by contact and 
airborne droplets, which infect nearby herds (34). Incidence of infection, or morbidity, is 
high, and M. hyopneumoniae has been shown to be present in 80% of swine at slaughter (29). 
It has been estimated that pneumonic pigs sell for $1.50 to $2.50 less on the United States 
market (78), giving a rough loss of $200 million per year to the U.S. swine industry (39). 
Swine infected with M. hyopneumoniae generally begin to resolve lesion 6 weeks after the 
first clinical signs and are thereafter resistant to recurring clinical signs due to repeat infection. 
The gross pathological findings of M. hyopneumoniae infection are purple to tan or gray areas 
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of consolidation (78). These lesions are caused by the host's response to mycoplasma 
colonization and are characterized microscopically by lymphocytic infiltration (22, 88). M 
hyopneumoniae infection appears to enable other, more severe infections by other respiratory 
pathogens such as swine influenza virus (91) and porcine reproductive and respiratory 
syndrome virus (PRRSV) (90). These cooperative infections cause a more severe pneumonia 
than either pathogen alone (79, 92). It is thought this occurs by an immunosuppressive 
mechanism, but this is still not clear. Mycoplasmas have been shown to be cytotoxic towards 
lymphocytes, act as non-specific mitogens, and alter regulation of cytokines (72). Some 
species contain superantigens (21) and others may induce autoimmunity (72). How and to 
what extent M hyopneumoniae may alter immune cell function has not been determined (92). 
Adhesion and Cell Surface 
Unlike other mycoplasmal species, M hyopneumoniae binds specifically to the ciliated 
cells of the swine lung ( 40) as evidenced by its intimate association with these cells by 
electron microscopy (55). Ciliated cell binding of M hyopneumoniae is specific for three 
sulfated glycolipids (La, Lb and Le) present in swine epithelial cilia (105). The M 
hyopneumoniae adhesin, P97, was identified using monoclonal antibodies (Mabs) capable of 
blocking adherence of M hyopneumoniae to ciliated cells (106). Damage to these cells, in the 
form of clumping, ciliostasis and eventual sloughing, is strongly suspected to be a direct result 
of binding, but this has not been not conclusively determined (25). A mechanism whereby M 
hyopneumoniae disrupts ciliated cell signaling pathways has been supported by the increase 
in calcium concentrations in bound swine ciliated epithelial cells exposed to virulent M 
hyopneumoniae but not to avirulent strains or to Mycoplasma flocculare ( 69). Other 
membrane components may also contribute to ciliated cell adherence because blocking of 
adherence by Mabs against the binding site of P97 is not complete. The cell surface of M 
hyopneumoniae is weakly hydrophobic, which has been thought to contribute to adherence 
(108), but it is likely that M hyopneumoniae contains more than a single adhesin that has yet 
to be identified. Like many other mycoplasmas, M hyopneumoniae is largely devoid of 
external structures, such as pilli and flagella, and lacks specialized organelles for attachment 
(58). However, M hyopneumoniae has been observed in vivo to have a thick mucilaginous 
capsule coating and long fibrial material on the surface of the cell, both of which have been 
thought to participate in attachment to swine respiratory epithelium (88). Strains that have 
lost pathogenicity through repeated passage in laboratory culture have also lost these 
structures and the ability to bind to cilia, suggesting they may have a role in adherence (59). 
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The outer barrier of mycoplasmas is a single lipid bilayer composed of 
lipopolysaccharides, lipoglycans, cholesterol and lipoproteins. Thus, it has a simpler 
structure than more typical bacteria, lacking both a cell wall and an outer membrane. Many 
membrane proteins in mycoplasmas are thought to be N-terminal cysteine-linked lipoproteins 
(86). These proteins are found in mycoplasmas linked to diacylglyceryl moieties by a 
thioester bond with cysteine (45), and seem to lack the N-acyltransferase found in other 
bacteria which is necessary to triacylate the terminal amino group with a third fatty acid chain 
(44, 96). The diacylated form is anchored in the membrane less securely than the triacylated 
proteins and is thought to facilitate the release of proteins into the extracellular space (96), 
which could facilitate communication, competition and environmental control (4). 
Lipoproteins are highly antigenic and thus, the target of humoral (16) and inflammatory (62, 
65) responses during infection. Experiments of host responses to M penetrans (64), M 
gallisepticum (44), M mycoides subsp. mycoides SC (1), and M bovis (8) infections have 
shown lipoproteins to possess strong immunogenicity. Polypeptide repeats in the protein 
portion of the lipoprotein are recognized by antibodies while the lipid moieties potentiate 
inflammatory response (62). Due to their position on the cell surface, lipoproteins may have 
roles in membrane structure, transport and adhesion. It has become clear that some 
mycoplasma lipoproteins are cleaved after being anchored in the cell membrane (14), and 
these cleavage events may stimulate functional changes in the molecules. This should not be 
surprising since M pneumoniae has genes homologous to transpeptidases in Staphylococcus 
aureus and Bacillus subtilis, which cleave the extracellular portion of transmembrane 
lipoproteins and incorporate the cleavage product into the peptidoglycan mesh ( 46). 
Antigenic Variation 
Antigenic variation or phenotypic switching is used by many invasive bacterial species to 
change the character of their cell surface to avoid host recognition (27). This is accomplished 
either by altering surface proteins in response to host signals which trigger the sensory 
systems of the bacteria during the infectious cycle (56, 75) or by a constant accumulation of · 
random mutations in surface protein genes that creates heterogeneous bacterial populations, 
part of which may escape the immune response (13, 75). Mutational genetic variation has 
been observed in mycoplasmas, which show impressive variation in their antigenicity that 
enables them to be very effective pathogens (98). Mycoplasmas have developed several basic 
strategies to produce antigenic variation. 
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Gene Families 
Bacterial pathogens have a base set of genes that are expressed as surface lipoproteins, 
each of which can appear several times in the genome as diversified gene families (87). These 
closely related genes, which can each give a different antigenicity to the bacteria, play the 
primary role in antigenic variation by providing a repertoire of genes to be further diversified 
by mechanisms specific to that organism (72, 102). Mycoplasma species, despite limited 
genome space for surface variation, have been shown to posses these families of genes in M 
hyorhinis (20), M pulmonis (l 0), M hominis ( 47), M gallisepticum (54), and M bovis (67). 
In M hyopneumoniae, a family of P97 adhesin homologues has been observed and their 
antigenicity studied (Minion et al., unpublished). Another level of variation is introduced by 
the modulation of the gene family members by size variation, phase variation and 
posttranslational processing to produce yet more variation in the surface features of the 
bacteria (72). Mycoplasmas have developed several basic strategies to producing antigenic 
variation. The most commonly used methods, size and phase variation of lipoproteins, are 
generally thought to play a role in immune evasion (102). 
Size Variation 
Size variation is enabled by variable expression of tandem repeat sequences in the 
lipoprotein gene due to homologous recombination and slipped-strand mispairing during 
DNA replication (16, 48, 77). This is a process which is subject to the high mutation rate of 
mycoplasmas (99) and is independent of expression so that a population of the bacteria has 
an ever-changing repertoire of variants ( 103 ). Variations in the size of surface proteins can 
change the bacteria's ability to avoid the host's immune response and host binding specificity 
(72). Changes in lipoprotein sizes has also been shown to give adaptive advantages to the 
infecting bacteria, such as in M hyorhinis where longer Vlp proteins were shown to protect 
against growth inhibiting antibiotics (19). In M hyopneumoniae, P97 lipoprotein has been 
shown to be variable in size due to alternate expression of redundant, five amino acid repeat 
regions (Rl) near the C-terminus ( 40, 97), which controls functionality in its part of cilium 
binding (39, 58). 
Phase Variation: Homopolymeric Repeats and Chromosomal Rearrangements 
Phase variation allows the bacteria to tum the expression of a protein on or off in such a 
way as to produce a variable population of cells as defined by their suface lipoprotein (72). 
Functional expression of surface proteins in mycoplasmas is subject to genetic control by 
several mechanisms, primarily controlled by high frequency, reversible mutations of repeat 
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regions (102). Mutations of homopolymeric repeats and oligonucleotide repeats can take 
place in the form of nucleotide insertions and deletions through slipped-strand mispairing 
during DNA replication of that region (74). These mutations have been found to occur in 
regulatory elements, causing changes in polymerase binding (102) due to changes in the 
distance between the -10 and-35 promoter boxes (20, 95), and in length of trinucleotide 
repeat tracts 5' of the -35 box (33, 50). Mutations within the coding region can also vary 
expression of surface proteins by insertion or deletion mutations during replication that cause 
a frame shift bringing stop codons into frame (104) or by point mutations of a GAA guanine 
residue to a UAA stop codon at residues of high mutability (12), resulting in a truncated, 
non-functional product. 
Phase variation in mycoplasmas can also be a function of DNA rearrangements. Site 
specific DNA inversions of promoter regions can create a phase variation of a gene or set of 
genes by random inversion events between oppositely-oriented, specific, recombination core 
sites located at the 3' end of the promoter region and the 5' end of each variable open reading 
frame (ORF)(l 0). Variation of surface proteins has also been observed to take place by site-
specific DNA inversions that separate regulatory elements from the dependant gene, leading 
to random switching of gene expression (51 ). Production of chimeric genes by recombination 
of homologous regions ofrelated genes(49) and by recombination of site-linked pseudogenes 
(66) has been shown to allow further diversification of antigenic character. Intergenic 
recombination is also thought to occur in the multigene operons of adhesin structural genes 
present in many mycoplasmas and has been theorized to occur between P97 copies in M 
hyopneumoniae ( 40). 
Posttranslational Processing 
Another, more recently discovered mechanism employed to diversify antigenic character 
is the use of differential cleavage of a single surface protein (14). In addition to size and phase 
variation, some gene products are varied by proteolytic cleavage of a specific site on the gene 
product, yielding lipoproteins of distinctly different sizes and immunological character (24). 
The model system for this mechanism is the 404 amino acid malp gene product of M 
fermentans which is differentially cleaved after being anchored in the cell membrane to yield a 
14 amino acid lipopeptide (14). Differential ratios of the whole and cleaved forms in the 
bacterial population give another level of antigenic variation (24 ). Genes homologous to malp 
have been observed in other mycoplasmal genomes (76), so it is believed that these and other 
gene products are modified in the same way (102). 
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Codon Usage 
Most mycoplasmas have a very low guanine (G) and cytosine (C) genome content, 
thought to be due to directional mutations in the adenine (A) and thymine (T) direction during 
their evolution (63). A functional feature of this is the tendency for A or T to be used 
preferentially in the third position of codons with wobble or even for the mycoplasma to 
show preferential codon usage for codons using a G or C to those using an A or T (28). M 
pneumoniae is an example of both of these tendencies among mycoplasmas with a G+C 
content of 40 mol% and the use ofUGA as the codon coding for the amino acid tryptophan 
instead of the much more common UGG usage (37, 72). Preference is shown for the use of 
UAA and UAG stop codons, and in the case of especially low G+C content mycoplasmas 
like M capricolum, further preference is shown for UAA ( 41 ). The preferential use of UGA 
as a tryptophan sense codon makes mycoplasmas difficult organisms to study; the frequent 
presence of what is considered as stop codons prevent full-length expression of gene 
products in alternate hosts, such as Escherichia coli ( 42). Early stop codons in mycoplasma 
genes could result in truncated protein products lacking essential three-dimensional structure, 
functional subunits and/or antigenic regions (11 ). This problem has been partially overcome in 
the past with the use of an opal suppressor tRNA and a tryptophan insertion enhancing 
mutation to release factor-2, which allowed a certain amount of read-through of premature 
stop codons (38, 60). More recently, this problem has been corrected by using site directed 
mutagenesis to mutate any in-frame TGAs to TGGs so that it will be expressed correctly as a 
tryptophan in eukaryotic systems (18, 76). Expression of functional mycoplasmal gene 
products is possible using these systems (76). 
DNA Vaccines 
The discovery by Wolff, et al. in their 1990 publication that plasmid DNA in saline 
solution could be injected and would be taken up by mouse skeletal muscles and express 
genes encoded on the plasmids has led to innovations in how an immune response can be 
elicited from a host (101 ). DNA vaccines ( or genetic vaccines) are double-stranded DNA 
plasmids capable of expressing an antigenic protein of the infecting organism, using the host's 
transcriptional and translational machinery. This foreign protein can then be recognized by 
the host's immune system to induce an immune response (6). The plasmids are primarily 
designed for mammalian hosts and as such, the vaccine plasmids would contain elements that 
would allow proper expression of the infecting virus or bacterial genes in the host's 
eukaryotic system (85). Several methods are commonly used for administration of the 
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plasmid mammalian hosts. Biolistic introduction of gold particles coated with DNA to the 
animal's epidermis provides a painless system for induction of immune response with a very 
small quantity of DNA (7). Direct intramuscular or intradermal injection by needle or by 
needle-less injector into skeletal muscles or beneath the skin, respectively, have been shown 
to elicit substantial immune response in a variety of animals, such as mice and dogs (23). 
Needle-less injection systems have been shown to provide a greater immune response in 
hosts to plasmids expressing proteins from a pathogen than injection by needle (5). In 
particular, the Biojector™ needleless syringe from Biojet has been shown to improve the 
immune response of rabbits to DNA vaccines delivered by intradermal injection over 
intramuscular injection with a needle (2, 52). 
DNA vaccines have been shown to elicit humoral immune response in animals by the 
repeatable presence of antibodies specific against the protein encoded on the plasmid (89). 
DNA vaccines encoding a M hyopneumoniae gene, corrected for tryptophan codon usage, has 
also been found to elicit humoral immune response in a murine model measured by greatly 
heightened immunoglobulin and interleukin levels (17). DNA vaccination has been thought to 
be a particularly suitable method for the treatment of chronic diseases, such as enzootic 
pneumonia, due to findings on the lengthy persistence of the plasmid in the skeletal muscle of 
an immunized host (100). 
The VR1020 (Vical, Inc., San Diego, Calif.) expression vector has been used as a reliable 
way to produce proteins in eukaryotic cells from a DNA source in mice (84), HeLa cells, and 
rabbits (71). Driven by an immediate-early cytomegalovirus promoter, genes inserted into the 
plasmid are expressed as fusion proteins with tP A sequences by the eukaryotic 
transcription/translation machinery of the host and directed to extracellular 
compartments(84). This seems to enhance the effectiveness of the expression vector over a 
similar construct that lacks the tP A sequences (Sreekumar and Minion, unpublished). 
Genomic Data and Analysis 
Genome sequencing has become a powerful tool in understanding molecular mechanisms 
of pathogens. There have been over 164 completed genomes published including 20 
eukaryotic, 127 eubacterial and 17 archaeal. It is estimated that there are 413 ongoing bacterial 
and 341 eukaryotic sequencing projects at the present time (9). The genome sequences of M 
pulmonis (15), M genitalium (30), Ureaplasma urealyticum (32), M pneumoniae (37), M 
penetrans (82) and M gallisepticum (68) have been reported. The genome of M 
hyopneumoniae strain 232A was sequenced by Dr. Greg Mahairas at the High Throughput 
Sequencing Center at the University of Washington, and gaps in the sequence were completed 
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and assembled in the Minion laboratory at Iowa State University. The total genome size is 
892,758 base pairs (bp) (Minion et al., unpublished). Other mycoplasma genomes being 
sequenced include M mycoides subsp. mycoides SC, M alligatoris, M capricolum, M 
fermentans, M haemofelis, M mobile, Morale, M synoviae, M bovis, Spiroplasma citri, 
and S. kunkelii ( 2 strains). 
The chief advantage of genome sequencing is mining the data for information on the 
genetic architecture of the organism and other features of its life style. Coding genes can be 
identified by comparison to other related genes in Genbank (http://www.ncbi.nlm.nih.gov/) 
by Basic Local Alignment Search Tool (BLAST) (3) or FASTA (70), as well as by programs 
that search the sequence for the components of a possible coding region in a favorable context 
such as Gene Locator and Interpolated Markov Modeler (GLIMMER) (26, 81). These allow 
the identification of sequences that have a high probability of being coding regions for genes 
of a function similar to matches in other organisms and genes that express proteins of 
unknown or hypothetical function. The translated protein sequence of these genes can be 
searched for protein motifs that suggest certain functions, such as transmembrane domains or 
ATP-Binding Cassette (ABC) transporters. Putative lipoproteins can be identified as well as 
other surface proteins. Annotation of the M hyopneumoniae genome has been completed. 
Figure 1 is a circular representation of the genome. 
Summary with Goals and Hypothesis 
Mycoplasma hyopneumoniae is an organism of great biological interest and economical 
concern. Further study of M hyopneumoniae is essential to understanding the nature of its 
disease in swine. Molecular data needs to be obtained about the organism and its component 
parts to yield more useful data in exploring the pathogenesis of the bacteria. My goal is to 
produce monospecific, polyclonal rabbit antisera against putative M hyopneumoniae 
lipoprotein gene products and then test those antisera to determine if the genes are being 
expressed in vitro and in vivo. This will be accomplished by cloning of the genes in E. coli, 
performing site directed mutagenesis to eliminate the TGA codons, and then using these 
altered gene sequences in a DNA vaccine to produce the desired antibodies in New Zealand 
White rabbits. The antisera will be screened by immunoblot and by indirect fluorescence 
histochemistry on tissues from infected pigs to examine expression. These tools will allow 
further examination of the efficacy of our DNA vaccines in immunization against M 
hyopneumoniae infection. 
--
-
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Figure 1. Circular representation of the M hyopneumoniae genome structure. The dnaA gene 
is at position one. Starting from the outside: circle one, replication arrows; circle two, the 
location of the putative coding sequences on the positive strand; circle three, the location of 
the putative coding sequences on the negative strand (the color code for the functional 
assignments are given in the figure); circle four, position and direction of transcription of the 
P97 (black) and P 102 (orange) paralogs; circle five , scale in bp; circle six, paralogous 
families of three or more members (colors indicate relationship and not functional 
assignment) ; circle seven, predicted lipoproteins . 
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MATERIALS AND METHODS 
Bacterial Strains, Media and Plasmids 
Mycoplasma strain 232A is strain 11 (53) passaged through pig number 232. Cultures 
and antigen preparations are from in vitro passage less than 15. It was grown in Friis media 
(31) . Escherichia coli strains used in this study were: TOPlO (mcrA !i(mcrCB-hsdSMR-mrr) 
(<j>80 lacZ!1Ml5) !1(lac)X74 deoR recAJ araD139 !1(ara-leu)7697 galU galK rpsL endAJ 
nupG F'[(tef)]) and XLl0-Gold (!1(mcrA)183 ti(mcrCB-hsdSMR-mrr)l 73 endAJ lac [F' 
proAB lacflZ!1Ml5 TnlO (Tet)J Amy]), and EP1300 (Epicentre, Madison, Wis.)(F- mcrA 
ti(mcrCB-hsdSMR-mrr) (<j>80 lacZ!iMJ 5) !1(lac)X74 recAJ araD139 !1(ara-leu)7697 galU 
galK rpsL endAJ nupG trfA]. They were grown in Luria-Bertani (LB) broth (1 % tryptone, 
0.5% yeast extract, 0.5% NaCl), 2XYT broth (1.6% tryptone, 1.0% Yeast Extract, 0.5% 
NaCl), or SOC broth (2% tryptone, 0.5% yeast extract, 0.203% MgCli-6 H20, 0.246% 
MgSO4- 7 H20, 0.36% glucose). Plasmid cloning vectors used in this study were pCR2.1-
TOPO (Invitrogen, Carlsbad, Calif.) and pSTBO78 (Merial S.A.S., Leons, France), a 
derivative of VR1020 (Vi cal, Inc., San Diego, Calif.). 
Reagents and Buffers 
Chemicals were obtained from Sigma Chemical Company (St. Louis, Mo.) and Fisher 
Scientific Company (Hanover Park, Ill.). Buffers were as follows: Tris-acetate ethylene 
diamine tetra-acetic acid (TAE) (0.04M Tris-acetate, 0.001M EDTA), TS-Tween (0.01 M 
Tris-0.140 NaCl-0.01 Tween 20); transfer buffer (20% methanol, 0.605% Tris, 2.88% 
glycine); sodiumdodecyl sulfate (SDS) running buffer (0.3% Tris, 1.44% glycine, 0.1% SDS); 
phosphate buffered saline (PBS) (0.115% dibasic sodium phosphate, 0.85% NaCl); 
Isopropyl-beta-D-thiogalactopyranoside (IPTG) stock solution was 100 mM; 5-bromo-4-
chloro-3-indolyl-beta-D-galactopyranoside (X-gal) stock solution was 40 µg per ml in N,N-
dimethyl formamide; azo dye counterstain (0.01 % Eriochrome black...T, 0.05% acetic acid, 
58% N,N-dimethyl formamide, 0.2% aluminum chloride),. 
Enzymes 
Restriction enzymes were obtained from Invitrogen, Stratagene Cloning Systems (La 
Jolla, Calif.), and Life Technologies, Inc. (Rockville, Md.) and used according to manufacturer 
specifications. Taq polymerase was obtained from New England Biolabs (Beverly, Mass.) or 
Bioline (Randolph, Mass.). Alkaline phosphatase was purchased from Invitrogen. Ligases 
were obtained from Invitrogen. Pfu polymerase was obtained from Stratagene Cloning 
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Systems. Alkaline phosphatase conjugated monoclonal Mouse anti-rabbit Immunoglobulin (y-
chain specific) was acquired from Sigma Chemical Company. 
Sequence Analysis and ORF Selection 
The M hyopneumoniae genome sequence used in this study was incomplete at the time 
the study began. Three gaps remained in the sequence, and analysis with GLIMMER v2.1 
software (The Institute for Genomic Research, Rockville, Md.) identified 735 putative open 
reading frames (ORFs). This number was subsequently reduced to 699 when closure was 
complete. The genes chosen for cloning and analysis was based on the original estimate. The 
basis for choosing these particular ORFs to study included homology to expressed genes in 
closely related organisms, presence of lipoprotein motifs, and presence of transmembrane 
domains. 
Primer Synthesis and DNA Sequencing 
Sequences from specific ORFs were chosen for cloning based on two factors: regions of 
protein antigenicity and TGA codon avoidance. Protein antigenicity plots were prepared for 
each ORF using Mac Vector 6.0 software (Eastern Kodak Company, Rochester, N.Y.) using 
the antigenic index algorithm (43) and TGA codons were mapped to the plot. The 
transmembrane domains near the amino terminus were also mapped to the sequence and were 
avoided if possible because they often cause cloning and expression problems in E. coli. 
Primers were sought with a desired melting temperature of approximately 75°C and a GC 
clamp at the 3' end. Primers were designed using the Oligo 5 software (National Biosciences, 
Inc., Plymouth, Minn.) and synthesized in a Model 399 DNA/RNA Synthesizer (Applied 
Biosystems, The Perkin-Elmer Corporation, Norwalk, Conn.) by Integrated DNA 
Technologies (Coralville, Ia.). The Iowa State University DNA Facility performed all DNA 
sequencing using cycle sequencing protocols and an automated Model 373 or 377 DNA 
sequencer (Applied Biosystems, The Perkin-Elmer Corporation). The deduced sequences 
were edited and assembled using AutoAssembler software (Applied Biosystems). 
Polymerase Chain Reactions 
In all cases except for the purpose of site directed mutagenesis, Taq DNA polymerase 
was used for polymerase chain reactions (PCR). The PCR mixtures contained IX PCR buffer 
provided by the company for their respective polymerases. In addition, 200 µM of dNTPs 
and 0.5 µM of each of the primers were added for each reaction, and the reaction volume was 
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kept constant at 50 µl. Generally, 1.5 mM of magnesium chloride was added to PCR 
reactions, but magnesium chloride levels were varied between 1 and 3 mM when required to 
obtain appropriate PCR products. PCR amplification cycles consisted of a 1 min denaturing 
step at 94 °C, followed by 30 cycles of 94 °C for 1 min, 45-65°C for 0.5 min and 72°C for 2 
min. The annealing step (45-65°C) was varied depending on the melting temperature (Tm) of 
the primers used. This was followed by an elongation step of 72°C for 10 min. A portion of 
the PCR reaction was analyzed on a 1.2% TAE buffered agarose gel to determine the size of 
the amplified product, and the remainder of the product was purified by size exclusion 
filtering (Centricon 30 microconcentrators; Amicon, Danvers, Mass.) or by gel extraction 
using Zymoclean gel recovery kit from Zymo Research (Homby, Ontario). 
pCR2.1 Plasmid Constructions 
Plasmid construction strategies were initially developed using the Gene Construction Kit 
2 software (Textco, Inc., N.H.). Desired DNA fragments were amplified by PCR from M 
hyopneumoniae genomic DNA and products of the correct size, as visualized on agarose gel, 
were purified. Purified PCR fragments were ligated with transport vector pCR2. l-TOPO 
using the pCR2.1 TA cloning kit according to manufacturer's specifications. Ligated plasmids 
were transformed into One Shot TOPI O competent cells from Invitrogen according to 
manufacturer' s specifications. Cells were plated on LB agar containing antibiotic and spread 
with 40 µl X-gal and 10 µl IPTG. Plates were grown overnight at 37°C, and clones were 
selected by blue/white screening. White colonies were picked into culture plates containing 
200 µl LB broth and grown a minimum of 6 hr. Clones were screened by PCR using less than 
1 µl of the cells as template and primers specific for vector sequences flanking the multiple 
cloning site. Clones that yielded the appropriate PCR product size were picked to 96 well 
plates, and plasmids were purified using the Montage Plasmid Miniprep96 Kit from 
Millipore (Billercia, Mass.) according to manufacturers directions. The entire insert was then 
sequenced to confirm the cloning. 
Mutagenesis 
Mutagenesis primers were designed according to specifications of the Quickchange Multi-
Site Mutagenesis kit (Stratagene) for each TGA found in-frame in each cloned region, based 
on the genomic sequence. The primers included approximately 15 homologous bp on each 
side of the TGA and substituted TGG instead of the TGA codon. In some instances multiple 
TGA codons were removed with the same primer if they were close in the sequence and if a 
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primer could be designed of less than 50 bp in length. The pCR2.1 clones were subjected to 
mutagenesis PCR using positive strand mutagenic primers and pfu polymerase, which 
replicated the entire plasmid, incorporating the mutations in the newly synthesized plasmid. 
In some reactions up to five mutagenic primers were added to the mutagenesis reaction. Non-
mutated template DNA was digested with restriction enzyme Dpnl, which specifically 
digests methylated template DNA. The newly synthesized, nonmethylated plasmid DNA 
was then transformed into XL-Gold (Stratagene) chemically competent cells by heat shock 
induction according to manufacturers specifications. Cells were grown on LB plates with 
kanamycin overnight. For sequencing, plasmids were prepared using a Qiagen (Valencia, 
Calif.) mini-plasmid purification kit according to the manufacturer's instructions. 
Mutagenesis of each site was screened by sequencing through the region of the mutation using 
flanking sequences as primer sites. Clones not shown to contain all desired mutations were 
subjected to subsequent rounds of mutagenesis until fully mutated. Each insert was fully 
sequenced for confirmation of the mutated sites and the ORF. 
pSTB078 Plasmid Constructions 
The inserts of the fully mutated ORFs were amplified by PCR and cloned into pSTB078 
as follows. Primers were designed based on the sequence of the fully mutated pCR2. l clones 
to amplify the cloned insert while incorporating a new, unique restriction site at each end of 
the fragment. Care was taken while designing these primers to include unique restriction sites 
absent in the insert and to allow in-frame insertion of the digested fragment downstream of 
the tP A sequence in the expression vector. PCR was performed on final pCR2.1 clones using 
the pSTBO78 cloning primers specific for each pCR2.1 construct, and the products of the 
appropriate size, as visualized on agarose gel, were purified. Each product was digested with 
restriction enzymes specific to sites incorporated during PCR, and ethanol precipitated. The 
pSTB078 vector was digested with the same enzymes, subjected to Antarctic alkaline 
phosphatase treatment to prevent self-ligation, and ligated with the digested, precipitated 
PCR products at a 1: 1 molar ratio of vector to insert. One unit of T4 DNA ligase was used 
per ligation reaction in a 20 µl volume that contained approximately 150 ng of vector DNA. 
Ligation mixtures were incubated overnight at 14 °C. After ligation, plasmids were digested 
with Asel to linearize reannealed vector, ethanol precipitated, and transformed into E. coli 
cells. 
Escherichia coli EP1300 electro-competent cells were thawed on ice, and 33 µl of cells 
were used in each transformation reaction with 60-150 ng of plasmid DNA. The plasmid 
DNA was mixed with electro-competent cells in chilled Bio-Rad 0.1 cm electroporation 
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cuvettes and pulsed once at 2.5 kV of charging voltage and 129 Ohms resistance using a 
Model ECM 600 Electro Cell Manipulator (BTX, San Diego, Calif.). The pulsed cell 
mixtures were diluted into 1 ml of SOC media and then incubated at 3 7°C for one hr prior to 
plating the transformation mixture onto LB agar containing 50 µg per ml kanamycin. 
Resulting colonies were picked into culture plates containing 200 µl LB and grown a 
minimum of 6 hr. Clones were screened by PCR using less than 1 µ1 of the cultured media as 
template and primers on the plasmid flanking the multiple cloning site. Clones containing 
inserts of the appropriate size, as visualized on agarose gel, were sequenced to verify 
identity. If expression frame was not correct, mutagenesis was performed as described above 
to restore proper reading frame. 
To prepare plasmids for animal vaccinations, E. coli clones were inoculated into 1 L 2X 
YT broth with 50 µg per ml kanamycin and grown overnight. Plasmids were isolated from 
bacterial cells using Megaprep Nucleobond Nucleic Acid Purification kit (BD Biosciences, 
San Diego, Calif.) according to manufacturer's directions for low copy plasmid purification. 
Isolated DNA was resuspended in PBS. The DNA concentrations were estimated by 
fluorometry (Model TKO 100, Hoefer Scientific Instrument, San Francisco, Calif.). 
Rabbit Vaccinations 
New Zealand White rabbits from Myrtle's Rabbitry Inc. (Thompson Station, Tenn.) 
were housed in individual cages at the Laboratory Animal Resource Facility, Iowa State 
University. All animal studies were conducted according to the guidelines of the Iowa State 
University Committee on Animal Care and Use. Prior to vaccination and bleeding, rabbits 
were sedated with 0.5-0.75 ml of a 1mg acepromazine per ml water. Each rabbit was 
vaccinated with 150 µg of one plasmid DNA in 1 ml of saline, per dose. Rabbits were 
vaccinated subcutaneously with a Biojector™ series 2000 needleless injector (Biojet Inc., 
Portland, Ore.). Animals were vaccinated 3 times at 4-week intervals. Blood was collected 
immediately before each injection from the ear vein. Four weeks after the final vaccination, 25 
ml samples of blood were taken once a week for two weeks. At sacrifice, rabbits were 
euthanized using 1-1.5 ml of 100 mg per ml ketamine and 0.1 mg per ml acepromazine in 
water and exsanguinated by cardiac puncture, collecting as much blood as possible. Blood in 
all cases were collected in BD Vacutainer blood collection tubes from Preanalytical Solutions 
(Franklin Lake, N.J.). The serum was separated by centrifugation at 2500 rpm for 10 min and 
frozen at -20°C. 
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Immunoblot 
Immunoblots were performed by the method of Towbin et al. (93). Whole cell lysates of 
M hyopneumoniae and Bio-Rad Precision Plus Protein standard were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) on mini-gels from Bio-Rad at 150 volts using the 
dye front as a marker of progress. The proteins were then transferred to nitrocellulose by 
electro blotting in transfer buffer at 100 volts for 30 min. The membrane was blocked in TS-
Tween buffer plus 5% powdered skim milk overnight to block protein-binding sites. The 
membrane was then cut into 5 mm wide strips, labeled and blocked a further 30 min. This 
was followed by a quick wash and three washes for 10 min with TS-Tween to remove excess 
milk solution. Membrane strips were then incubated with rabbit sera diluted in TS-Tween 
with 5% mycoplasma free swine serum overnight at room temperature in 5 ml tubes on a 
rocker. Nitrocellulose strips were then washed briefly in TS-Tween to remove excess antisera 
and then subjected to three washes in TS-Tween for 10 min each before incubation in 1 :3000 
diluted alkaline, phosphatase conjugated mouse anti-rabbit secondary antibody in TS-Tween 
for 2 hr. The secondary antibody was removed and the nitrocellulose was washed with TS-
Tween to remove excess secondary antibody and subjected to three washes in TS-Tween for 
10 min. Nitrocellulose was then developed in AP substrate (Naphthol 0.03 g-Fast Red 0.06 g 
in 60 mls of 20 mM Tris-HCl; pH 8.0) until bands had developed a purple color. The 
reaction was halted by transferring strips to distilled water and washing several times. 
Nitrocellulose was air-dried overnight on absorbent towels. 
Imm unofluorescence 
Swine lung tissue from M hyopneumoniae-infected pigs was acquired from Dr. Eileen 
Thacker at Iowa State University. The tissues had been prepared for histochemistry by flash 
freezing in Optimum Cooling Temperature (OCT) embedding medium (Miles, Elkhart, Ind.). 
Tissues were cross-sectioned to a thickness of 5 µm on a Leica Cryostat Cryocut 1800 (Leica 
Microsystems Inc., Exton, Penn.). Tissues were fixed to glass slides for 10 min at-23°C in 
ethanol, dried at room temperature and stored at -20°C. To perform immuno-binding, tissues 
were thawed at room temperature and each tissue cross-section was incubated for 30 min at 
3 7°C with 150 µl rabbit sera diluted 1 :20 in PBS. Slides were rinsed twice for five min in PBS 
at pH 7.4 with stirring and dried at room temperature. Each tissue cross-section was then 
incubated with 150 µl Alexa Fluor 488-labeled goat anti-rabbit IgG (Molecular Probes, 
Eugene, Ore.) diluted 1 :80 in PBS for 30 min. Tissues were then rinsed twice for five min in 
PBS with stirring. Wet tissues were placed in 500 ml azo dye counterstain for 30 sec with 
agitation. Tissues were rinsed twice with distilled water for two min with stirring and dried at 
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room temperature under a fume hood. Slide covers were applied with glycerin and sealed with 
clear fingernail polish. Tissue staining was read and results recorded using a Leica TCS NT 
confocal microscope. 
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RESULTS 
Sequence Analysis and ORF Selection 
Analysis of the predicted M hyopneumoniae ORFs by motif searching identified a group 
of approximately seventy gene products that had potential surface locations. This analysis 
was performed on an intermediate genome sequence with three gaps. From this group, a 
subset of predicted ORFS was chosen for further study most of which were lipoproteins. 
This resulted in a group of 34 ORFs of various sizes (Table 1 ). Once the genome sequence 
was completed, each of the ORFs was confirmed by BLAST analysis. Interestingly, one of 
the original ORFs actually represented a misaligned low quality sequence at the end of one 
contig found elsewhere in the genome (ORF536). This was not determined until late in the 
process so these results include two clones and resulting antisera from ORF 536. They are 
distinguished by referring to positive and negative strand clones. 
Rather than attempt to clone the complete gene with amino terminal membrane domains 
that are frequently unstable in E. coli, a segment of each ORF was targeted that contained the 
antigenic regions as defined by antigenic index algorithms in Mac Vector software and, if 
possible, reduce the number of TGA codons in the final product. This reduced the amount of 
work needed to provide the major antigenic regions of each ORFs; site-directed mutagenesis 
would have to be performed on each of these sites to allow full-length expression in the 
mammalian host. Also part of the equation was the design of PCR primers in the appropriate 
regions for cloning purposes. This sometimes was difficult because of the high AT content of 
the M hyopneumoniae genome. To expedite final plasmid constructions, a dual cloning 
approach was chosen. The gene segments would first be cloned into pCR2.1, a TA cloning 
vector that could accept PCR fragments. Site-directed mutagenesis would then be performed 
on this construct, and then the final sequences would be cloned in-frame into pSTB078, the 
mammalian expression vector. 
pCR2.1 Plasmid Constructions 
The cloning of the M hyopneumoniae gene segments into pCR2.l (Figure 2) followed 
manufacturer's directions. Primers designed for cloning are described in Table 2. Gene 
Construction Kit software was used to facilitate the cloning strategy and provide diagrams for 
primer design, restriction analysis, etc. The screening strategy was based on PCR analysis 
using vector-specific and insert-specific primers. Routinely ten or more colonies were picked 
from each transformation plate, analyzed by PCR and the positive clones DNA sequenced at 
both ends. Table 3 describes the plasmids constructed in pCR2. l . 
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Table 1. Open reading frames. 
ORF mhp number ORF Length Strand Protein Functional Motifs 
026 182 Reverse ATP/GTP-binding site, ABC transporter 
037 2009 Forward Putative Lipoprotein 
048 428 Forward ATP/GTP-binding site, ABC transporter 
072 1880 Forward Heat shock hsp70 protein 
108 3029 Forward Putative Lipoprotein 
147 1442 Reverse Putative Lipoprotein 
170 1049 Reverse Putative Lipoprotein 
216 263 Reverse Putative Lipoprotein 
262 746 Reverse Putative Lipoprotein 
271 3155 Forward Putative Lipoprotein 
336 1469 Reverse Putative Lipoprotein 
345 629 Reverse Putative Lipoprotein 
366 1664 Reverse Putative Lipoprotein 
369 743 Reverse MIP family 
379 929 Forward Putative Lipoprotein 
391 1184 Forward ATP/GTP-binding site 
424 1145 Reverse Putative Lipoprotein 
444 1769 Forward ATP/GTP-binding site 
465 938 Reverse Putative Lipoprotein 
466 2060 Reverse Putative Lipoprotein 
467 713 Reverse Putative Lipoprotein 
499 1049 Reverse ATP/GTP-binding site, ABC transporter 
51 I 1256 Forward Putative Lipoprotein 
512 1535 Forward ATP/GTP-binding site, ABC transporter 
536 245 Forward Putative Lipoprotein 
536 245 Reverse Putative Lipoprotein 
554 4262 Reverse Putative Lipoprotein 
555 833 Reverse ATP/GTP-binding site, ABC transporter 
559 1331 Reverse ATP/GTP-binding site, ABC transporter 
624 1511 Forward Putative Lipoprotein, G-protein coupled receptor 
677 1880 Forward Putative Lipoprotein 
681 1682 Forward Putative Lipoprotein 
684 3950 Reverse Putative Lipoprotein 
695 1076 Reverse Putative Lipoprotein 
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Table 2. Cloning Primers. 
Primer Designation Primer Sequence (5'-3') 
277-F TITCTAATAGCAGTAGTIT 
277-R GAATITATIATIATAGCACA 
210-F TIAGTIAACAGTCTCGGCTIA 
210-R ATAMGGCGTITCTIATIT 
170-F AMGTITTAAGTGGGGTITA 
170-R CGATCAGCGATICCGATAAC 
094-F TIAGCMAAGGCGTGATA 
094-R AGGCGATTTGGGTGATI 
046-F TICTTICGGGATCAATA 
046-R MAMTAAGTMAAGTGGC 
37A-F ATAGACCCMCCAMCCAAT 
37A-R CTAMTITCCTGTICAAGAATCAAG 
600-F TCTGGTCCGGTATCTAGTICG 
600-R TCGCCTTIGATCATITGTCTI 
574-F CMAATGAAGGGCMAM 
574-R GCTGGTAMTIATAGCGAMT 
573-F TCTGATIGGATITTGGAA 
573-R CCACTATMTAMTCTIACCT 
527-F GCAGGTIGTGGACAGACAGAA 
527-R TTTGCTTTTAGTICGTITTCG 
500-F MAATITMAATGMAATG 
500-R AGATCAMTGCAACATMAATAC 
001-F GAGMAMTATGGAACTCGG 
001-R AAGTTTCTTTTGCGCTTTG 
481-F CAGGCTGAMCTCTTTTA 
481-R AGCMTITCGAATCMCACTA 
410-F TATGCCAATIACMAATAGA 
410-R AGCGCTMAACTICATCAA 
354-F ATTIAGCACTAGGCGATIC 
354-R GAACITGITCCGCTITCT 
347A-F GTIGCCTTIAMTCCGATGTCT 
347A-R GTTTCCTTTTGGAMTAAGGG 
Genomic Cloning Primers (Direction/ORF Number) 
Forward/ORF 048 
Reverse/ORF 048 
Forward/ORF I 08 
Reverse/ORF 108 
Forward/ORF 147 
Reverse/ORF 147 
Forward/ORF 216 
Reverse/ORF 216 
Forward/ORF 262 
Reverse/ORF 262 
Forward/ORF 271 
Reverse/ORF 271 
Forward/ORF 444 
Reverse/ORF 444 
Forward/ORF 466 
Reverse/ORF 466 
Forward/ORF 467 
Reverse/ORF 467 
Forward/ORF 511 
Reverse/ORF 511 
Forward/ORF 536 
Reverse/ORF 536 
Forward/ORF 536 (neg. strand) 
Reverse/ORF 536 (neg. strand) 
Forward/ORF 555 
Reverse/ORF 555 
Forward/ORF 624 
Reverse/ORF 624 
Forward/ORF 677 
Reverse/ORF 677 
Forward/ORF 684 
Reverse/ORF 684 
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Table 3. Plasmid pCR2.1 derivatives produced during this study. 
Plasmid Genotype or phenotype Source 
pCR2.l- TOPO AmpR, KanR Invitrogen 
pISM2313 pCR2.1: 048, AmpR, KanR This Study 
pISM2312 pCR2.1: 108, AmpR, KanR This Study 
pISM2311 pCR2.l: 147, AmpR, KanR This Study 
pISM2309 pCR2.l: 216, AmpR, KanR This Study 
pISM2308 pCR2.1: 262, AmpR, KanR This Study 
pISM2306 pCR2.l: 271, AmpR, KanR This Study 
pISM2330 pCR2.1: 444, AmpR, KanR This Study 
pISM2329 pCR2.1: 466, AmpR, KanR This Study 
pISM2328 pCR2.l: 467, AmpR, KanR This Study 
pISM2325 pCR2.1: 511, AmpR, KanR This Study 
pISM2300 pCR2.1: 536, AmpR, KanR This Study 
pISM2323 pCR2.l: 536, AmpR, KanR This Study 
pISM2320 pCR2.l: 555, AmpR, KanR This Study 
pISM2319 pCR2.1: 624, AmpR, KanR This Study 
pISM2317 pCR2.l: 677, AmpR, KanR This Study 
pISM2314 pCR2.1: 684, AmpR, KanR This Study 
pUC origin 
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EcoRI 
Lacz gene 
pCR 2.1 
(3929 bp) 
fl origin 
Kanamycin 
M13 Reverse Primer BamHI 
CAGGAAACAGCTATGACCATGATTACGCCAAGCTTGGTACCGAGC TCGGATCCACTAGTAACGGCCGCCAG 
GTCCTTTGTCGATAC TGGTACTAATGCGGTTCGAACCATGGCTCGAGCCTAGGTGATCATTGCCGGCGGTC 
EcoRI 
PCR Product 
TA Cloning Site EcoRI EcoRV Not/ 
TGTGCTGGAATTCGGC TT NNNNNNNNNNNNAA GCCGAATTCTGCAGATATCCA TCACACTGGCGGCCGCT 
ACACGACCTTAAGCCGA ANNNNNNNNNNNNTT CGGCTTAAGACGTCTATAGGTAGTG TGACCGCCGGCGA 
Xbal M13 Forward Primer 
CGAGCATGCATCTAGAGGGCCCAATTCGCCCTATAGTGAG TCGTATTACAATTCACTGGCCGTCGTTTTAC 
GCTCGTACGTAGATCTCCCGGGTTAAGCGGGATATCACTCAGCATAATGTTAAGTGACCGGCAGCAAAATG 
Figure 2. Map of pCR2.1-TOPO cloning vector used for initial cloning from genomic DNA. 
TA Cloning Site represented by a series ofNs indicates the dephosphorylated T-overhang 
ends of the linear plasmid into which PCR products are ligated. 
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Muta genesis 
Ten of the pCR2.l clones containing segments of predicted lipoproteins also contained at 
least one in-frame TGA codon. These were removed by PCR-based site directed mutagenesis 
using primers designed to incorporate G nucleotides in place of the A in TGA to produce 
tryptophan-encoding TGG codons (Table 4). In some instances multiple mutagenic primers 
were added to the reactions to reduce the number of reactions needed. Mutated pCR2.1 
clones were sequenced across mutation sites to verify each mutation. Clones containing less 
than the desired number of mutations were stored and used as template for subsequent 
rounds of mutagenesis until fully mutated pCR2.1 clones (Table 5) were achieved. 
pSTB078 Plasmid Constructions 
To move the mutated sequences to the final expression vector pSTB078 (Figure 3), 
primers were designed to amplify the mutated gene segments while incorporating restriction 
enzyme digestion sites specific to each clone (Table 6). The primers were designed so that 
digested inserts were inserted in-frame with the tPA sequences of the expression vector. Also, 
the restriction sites were chosen based on the availability in the multiple cloning site and the 
lack of restriction sites within the insert. Amplified inserts were digested with these two 
restriction enzymes and ligated with similarly digested, dephosphorylated pSTBO78. 
Colonies showing the proper sized fragment when screened by PCR were grown and their 
plasmids prepared for sequencing. Sequence analysis revealed the identity of the clone, as 
well as the expression frame. In some instances, fragments were cloned into pSTBO78 with 
insertions or deletions at their 5' ends, which disrupted the frame of expression. These 
mistakes were corrected by further rounds of mutagenesis, using a primer matching the 
desired 5' junction of insert and cloning vector, to achieve the desired, in-frame clone. Clones 
with the correct expression frame (Table 7) were verified by sequencing the entire insert. 
Table 4. Mutagenesis primers. 
Primer 
Designation 
Primer Sequence (5'-3') 
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Primer Function (ORF 
Number/Genome Position) 
F37A/205 
F37A/418 
GCl 11111 lGCTAATICTGACTATIGGACAATCAAAAATCACCTITTAG Mutation of ORF 271 /207 
CAAAA TITIAAAGTCAAA TTICAATI ATGGCAAAAATTIGCAAAC 
GGGGATATAGC 
F046/369/378 CCAATAATTTGGCCAGTTTGGTIGCACCGTIATG 
F 170/619 GGAATIGCAATCGTCTGGATIACCCATAGAAT 
F2 l 0/886 GAAATAATIAAGTGGATAAAAGCGGAAC 
F210/ 1204 GTIGATATCTCAAAGTGGGTCCAACAAAAAC 
F210/1357 GAAAATICAGCAGCGTGGACTAGTAAAAAACTAG 
F210/1627 GTTIAGGAAAAGCAATTIGGAAAGTGCTIAATATICAGCG 
F2 l 0/2500 CTIGGGCCTAATICCTGGAAGCCAATAAAAAAT 
F2 l 0/2698 ATIATCAAAACTCCGTGGTCAGTIGAAATIAGTGC 
F3 4 7 A/ 1219 GCAAGTGTTICAGCTTGGTCT AACTI AGATCAAG 
F347 A/1729 GTAACAATIAGTCTTTGGTCAAGTTICTTIGGTG 
F3 54/322 GGACAACAACAGAAAACTGGCTTIACCTICTIAA TCC 
F354/553 
F354/925 
F500/28 
F527/316 
F527 /223 
F527/775 
F574/346 
F574/1396 
F574/1573 
F574/1624 
F600/808 
F600/928 
F600/1174 
AATGAATTIAAAAAATGGGCAAGTATAATAAAAC 
GTCTATGATAAAAGTATTIGGAATGATICTGATAAAAAT 
CCCAAAATTIAAAATGGAAATGTAAAAAGGAGA 
CCGGATAATCCTCGATGGATIAGTGCCCAAAAAG 
GCACAAAATAACTGGCTCACTCAGCAAGC 
GCTGTTIATGTCCCAGGATGGAATIATGGAACTGCCG 
CATATCTAGCAAAAAATIGGTIGTITTIATIAGAA 
ATITTIAATGCAATCTGGAAAAATAACGATAAAG 
GTAAGCCAAAATTGGCTITTIATICTCG 
CTIACATICCATAAATGGTACACTITICCTGATC 
ATITTIAATTICCCATGGGAAGTIAAAAAAGTCG 
GATGTIGTCCl 1111 l'GGAGCTIAGACCAAGG 
GCAAAGGATCTCGAAAAATGGTCTITTGATATICTIAGC 
Mutation of ORF 271/420 
Mutation of ORF 262/309 
Mutation of ORF 147/537 
Mutation of ORF 108/888 
Mutation of ORF 108/ 1206 
Mutation of ORF 108/1359 
Mutation of ORF 108/1629 
Mutation of ORF 108/2502 
Mutation of ORF 108/2700 
Mutation of ORF 684/1182 
Mutation of ORF 684/1692 
Mutation of ORF 677/324 
Mutation of ORF 677/555 
Mutation of ORF 677/927 
Mutation of ORF 536/21 
Mutation of ORF 511/210 
Mutation of ORF 511/303 
Mutation of ORF 511/762 
Mutation of ORF 466/350 
Mutation of ORF 466/1400 
Mutation of ORF 466/1577 
Mutation of ORF 466/ 1628 
Mutation of ORF 444/810 
Mutation of ORF 444/924 
Mutation of ORF 444/1176 
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Table 5. Mutated plasmids. 
Plasmid 
plSM2346 
pISM2345 
pISM2343 
pISM2341 
pISM2360 
pISM2359 
plSM2356 
plSM2354 
pISM2350 
plSM2347 
Genotype or phenotype 
pISM2312: 108: 888;1206;1359;1629;2502;2700, AmpR, KanR 
pISM2311: 147: 537, AmpR, KanR 
pISM2308: 262: 309;318, AmpR, KanR 
pISM2306: 271: 207;420, AmpR, KanR 
pISM2330: 444: 810;924;1176, AmpR, KanR 
pISM2329: 466: 350;1400;1577;1628, AmpR, KanR 
pISM2325: 511: 210;303;762, AmpR, KanR 
pISM2323: 536: 21, AmpR, KanR 
pISM2317: 677: 324;555;927, AmpR, KanR 
pISM2314: 684: 1182;1692, AmpR, KanR 
*Plasmid designations ofpCR2.1 clones containing TGA codons mutated to TGG. 
Genotype/phenotype descriptions include the pCR2.1 clone that was mutated: ORF number 
of the cloned gene: the position of each mutation relative to the first base pair of the ORF, 
resistances. 
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Table 6. Cloning Primers for pSTB078 vector. 
Primer1 Primer Sequence (5'-3') Plasmid ORF2 
PC277-F GGAAITCGGATCCTTICTAATAGCAGTAG pISM2379 048 (BamHI) 
PC277-R TGTGATGGATATCTGCAGAATTCAGCIT pISM2379 048 (EcoRI) 
PC210-F2 GGAGITCGGATCCITAGITAACAGTCTCGGC pISM2378 108 (BamHI) 
PC210-R2 GCAGAATTCAGCTTATAAAGGCGTITC pISM2378 108 (EcoRI) 
PC170-F GGAAITCGGATCCAAAGITITAAGTGGG pISM2377 147 (BamHI) 
PC170-R TGGATATCGCGGCCGCTCAGCITCGATCAGCG pISM2377 147 (Notl) 
PC094-F GGAAITCGGATCCTITAGCAAAAGGCG pISM2375 216 (BamHI) 
PC094-R TGTGATGGATATCTGCAGAATTCAGCIT pISM2375 216 (EcoRI) 
PC046-F GGAAITCGGATCCTTICTITCGGGATCAATAGGG pISM2374 262 (BamHI) 
PC046-R TGTGATGGATATCTGCAGAATTCAGCIT plSM2374 262 (EcoRI) 
PC37A-F GTGCTGGAATTCGGCITCTAAAITTCC pISM2372 271 (EcoRI) 
PC37A-R GAAITCGGATCCAITGGTTIGGITGGG plSM2372 271 (BamHI) 
PC600-F2 GTGTGCTGGATCCTCTGGTCCGGTATC pISM2396 444 (BamHI) 
PC600-R2 CTGCAGAATTCGGCTTTCGCCTTTGATC plSM2396 444 (Notl) 
PC574-F TCTGCGGATCCCGGCTTCAAAATGAAGGGC plSM2395 466 (BamHI) 
PC574-R CCAGGCGGCCGCAAITCAGCITGCTGGTAAATTATAG plSM2395 466 (Natl) 
PC573-F GGAAITCGGATCCTCTGAITGGAITITGGA pISM2394 467 (BamHI) 
PC573-R TGTGATGGATATCTGCAGAATTCAGCIT plSM2394 467 (EcaRV) 
PC527-F GGAAITCGGATCCGCAGGITGTGGACAG plSM2391 511 (BamHI) 
PC527-R TGTGATGGATATCTGCAGAATTCAGCIT pISM2391 511 (EcaRV) 
PC500-F2 GGAGITCGGATCCCAAAATTIAAAATG pISM2366 536 (BamHI) 
PC500-R2 CTGCAGAATTCGGCITAGATCAAATGCAAC pISM2366 536 (EcaRI) 
PC00l-F AAITCGGATCCCITGAGAAAAATATGG plSM2389 536 (-) (BamHI) 
PC00l-R GCCAGGCGGCCGCAATTCAGCITAAGTITCTITTGC pISM2389 536 (-) (Natl) 
PC481-F GGAATTCGGATCCCAGGCTGAAACTC plSM2386 555 (BamHI) 
PC481-R TGTGATGGATATCTGCAGAATTCAGCIT plSM2386 555 (Natl) 
PC410-F AGTGTGCGGCCGCITCAGCITAGCGCTAAAACTTCATC plSM2385 624 (Notl) 
PC410-R AAITCGGATCCTATGCCAAITACAAAATAG plSM2385 624 (BamHI) 
PC354-F GGAAITCGGATCCITAITTAGCACTAGGC pISM2383 677 (BamHl) 
PC354-R TGGATATCGCGGCCGCTCAGCITGAACITG pISM2383 677 (Natl) 
PC347A-F GGAGTTCGGATCCGITGCCITTAAATCCG plSM2380 684 (BamHI) 
PC347A-R GCAGAATTCAGCTTGTTTCCITITGG pISM2380 684 (EcaRI) 
1 F = Forward, R = Reverse 
2 Restriction sites added are in parenthesis; (-)=negative strand 
CMV prom / ehn / int 
Expression Start Codon 
tPA Signal 
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Asel Noll 
tPA signal 
pSTB078 
(5113 bp) 
GBH Terminator 
CTGTGAAGCAATC ATG GAT GCA ATG AAG AGA GGG CTC TGC TGT GTG CTG CTG CTG TGT GGA 
BamHI Asel 
GCA GTC TTC GTT TCG CCC AGC GGT ACC GGA TCC GGT CCG TTT CCC TGG CGC GCC TAA TTA 
Noll EcoRI EcoRV Xbal Terminator 
ATT AAG CGG CCG CGA ATT CGA TAT CCT CTA GAC ACG TGC TGC A~A :: : 3:: ~ - ~ ~- -
Figure 3. Map of expression vector pSTB078 . Shown are the restriction sites used to clone 
PCR fragments. The first arrow in the sequence indicates the start site of expression of the 
tPA/cloned insert fusion protein. The second arrow indicates the beginning of the GBH 
Terminator region. 
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Table 7. Expression plasmids. 
Plasmid Genotype or phenotype Source 
pSTBO78 KanR Merial 
pISM2379 pSTBO78: pISM2313 : 048, Kan R This Study 
pISM2378 pSTBO78: pISM2346: 108, Kan R This Study 
pISM2377 pSTBO78: pISM2345: 147, Kan R This Study 
pISM2375 pSTBO78: pISM2309: 216, Kan R This Study 
pISM2374 pSTBO78: pISM2343: 262, Kan R This Study 
pISM2372 pSTBO78: pISM2341: 271, KanR This Study 
pISM2396 pSTBO78: pISM2360: 444, Kan R This Study 
pISM2395 pSTBO78: pISM2359: 466, Kan R This Study 
pISM2394 pSTBO78: pISM2328: 467, KanR This Study 
pISM2391 pSTBO78: pISM2356: 511, Kan R This Study 
pISM2366 pSTBO78: pISM2300: 536, KanR This Study 
pISM2389 pSTBO78: pISM2354: 536, KanR This Study 
pISM2386 pSTBO78: pISM2320: 555, Kan R This Study 
plSM2385 pSTBO78: pISM2319: 624, Kan R This Study 
pISM2383 pSTBO78: pISM2350: 677, KanR This Study 
pISM2380 pSTBO78: pISM2347: 684, Kan R This Study 
plSM2434 pA009: 170, Kan R Merial 
pISM2435 pA00l: 072, KanR Merial 
pISM2436 pA012: 037, Kan R Merial 
pISM2437 pA002: 026, Kan R Merial 
pISM2438 pA003: 695, KanR Merial 
pISM2439 pA013: 681, KanR Merial 
plSM2440 pA015: 559, Kan R Merial 
pISM2441 pA004: 554, KanR Merial 
pISM2442 pA016: 512, KanR Merial 
plSM2443 pA005: 499, KanR Merial 
pISM2444 pA019: 465, KanR Merial 
pISM2445 pA007: 424, KanR Merial 
plSM2446 pA020: 391, Kan R Merial 
plSM 2447 pA017: 379, KanR Merial 
pISM 2448 pA008: 369, KanR Merial 
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Table 7. Expression plasmids (continued). 
pISM 2449 
pISM 2450 
pISM 2451 
pA024: 366, KanR 
pA021 : 345, KanR 
pA025: 336, KanR 
Merial 
Merial 
Merial 
*Plasmid designations of pSTBO78 expression vector and constructs produced using 
pSTBO78. Genotype/phenotype descriptions for constructs produced in this study 
include the cloning plasmid used: plasmid designation of pCR2.1 construct used to 
clone from: ORF number, resistances. Genotype/phenotype descriptions for 
constructs received from Merial include their plasmid designation: ORF number, 
resistance. 
Rabbit Vaccinations 
Rabbits were vaccinated with 100 µg plasmid DNA according to the schedule shown in 
Table 8, and blood was collected as listed. None of the rabbits showed distress or other 
effects from the vaccinations. Serum was collected following clotting, aliquoted and stored at 
-20°C. 
Table 8. Vaccination and bleeding schedule for rabbits. 
Week 4 8 12 13 14 
Blood Collected 15ml 15ml 15ml 25ml 25ml Sacrifice 
Serum "Pre Bleed" "1st Bleed" "2nd Bleed" "Final Bleed" "Final Bleed" "Final Bleed" 
DNA Injected 150 µg 150 µg 150 µg 
Immunoblot 
To test the antisera and determine if M hyopneumoniae was expressing specific gene 
products, immunoblots were performed and developed as described previously. ORF 
numbers and the expected size of full-length protein products are shown in Table 9. Figure 4 
shows the results of the immunoblotting studies with whole cell antigen from M 
hyopneumoniae strain 232. The reactivity of the antisera varied significantly; only a few gave 
strongly reactive bands. Dilutions of rabbit sera in TS-Tween were varied to enhance the 
banding patterns and minimize non-specific, background bands. Experimentation with amount 
of antigen resolved yielded 90 ug as the optimal amount for the single, wide laned gels used 
when blotted with antisera against proteins larger than 20 kD. To resolve several of the 
smaller ORFs such as 170, 216, 536 and 536 (negative strand), it was necessary to blot 
against a total of 240 ug antigen which had been partially resolved on the polyacrylamide gel 
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Table 9. Predicted sizes of protein products. 
ORF KDa ORF kDa ORF kDa 
026 89,193 366 64,394 536 (-)* 9,775 
037 78,283 369 27,139 536 9,775 
048 16,730 379 36,013 554 20,857 
072 68,873 391 46,086 555 31,521 
108 116,172 424 43,899 559 51,688 
147 57,309 444 68,717 624 57,400 
170 23,444 465 37,487 677 71,128 
216 16,621 466 82,333 681 65,534 
262 29,818 467 27,680 684 149,974 
271 118,835 499 39,447 695 41,969 
336 58,123 511 46,347 
345 24,096 512 56,615 
* (-) = negative strand 
(shorter run time to maximize separation in the low molecular weight bands) with more 
concentrated antiserum. 
In Figure 4, nitrocellulose strips are arranged in panels with the molecular size markers 
from the same gel to maintain size reference. The size of the protein was compared against 
the predicted size of the protein product from the expression constructs (Table 9). 
Interpretation of the immunoblots was complicated by two issues. Many of the antisera 
showed multiple bands even in the prebleed sera. Also, most of the antisera had low levels of 
protein-specific antibodies requiring low dilutions to be used in the immunoblots. In figure 4, 
black arrows indicate instances where the size matched closely with the expected size. Non-
filled arrows indicate bands which are unique to the final bleed serum, but of a smaller than 
expected size. 
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Twenty-one of the thirty-four antisera tested showed unique bands in the final bleed. The 
immunoblot patterns are given for these in Figure 4. The antisera against mhp511 was one 
exception. It was used at a dilution of 1 :5000 and stilled showed strong reactivity (Figure 4). 
Other antisera showed stronger reactivity to larger than expected proteins than with proteins 
of the expected size (ORFs 262,624, 336, 170, 379 and 369, read upper left to lower right in 
Figure 4). Twelve antisera showed a single unique band in the final bleed (ORFs 511,554, 
681,262,345, 677,536,216, 170,536,424 and 369). Five antisera showed a band at the 
expected protein size, as well as other smaller, unique bands (ORFs 624, 336, 072, 466, and 
559). Two antisera only show unique bands smaller than the proteins size expected (ORFs 
108 and 366). Many antisera recognized unique bands larger than the exected size (ORFs 554, 
681 , 624, 345, 336, 536, 216, 170, 536,379,369). For one of the antisera, mhp466, pebleed 
sera was not available for the immunoblot studies. Thirteen antisera tested showed no 
discernable unique bands as visualized by immunoblot (ORFs 026, 037, 048, 147,271,391, 
444,465, 467, 499, 512, 555. and 695)(data not shown). 
Imm unofluorescence 
The antisera were also used in immunofluorescence studies on M hyopneumoniae-
infected lung tissues. At least two and sometimes as many as five sections were subjectively 
scored by fluorescence intensity subjectively. Prebleed intensity averages were taken from 1-
2 different tissues. Measurements were made in units ranging from O to 10, as visually 
compared to the intensity of a anti-M hyopneumoniae positive control polyclonal rabbit 
hyperimmune antisera and the prebleed sera from each cognate rabbit. For each rabbit, the 
prebleed intensity average was subtracted from the final bleed intensity average to give a 
value for the difference in intensity. These values were grouped into four classes based on 
visual judgment calls as to the level of antibody binding; negative (0-1 .9), weakly positive (2-
2.99), moderately positive (3-3.99) or strongly positive (4 or more). These results are shown 
in Table 10. 
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Figure 5. Example oflmmunofluorescence assays on M hyopneumoniae-infected swine lung 
tissue. Panels A, D and G, rabbit anti-ORF 555 prebleed, rabbit anti-ORF 555 final bleed, 
rabbit hyperimmune anti-M hyopneumoniae, respectively.; Panels B, E and H, azo dye 
counterstained section; Panels C, F and I , merged image. Note the foci of infection. 
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Table 10. Results of immunofluorescence with rabbit antisera. 
ORF Rb No. Results1 , , ORF Rb No. Results 
026 3564 ± 444 3627 
037 3588 ± 465 3576 + 
048 3575 466 3567 + 
072 3587 +2 467 3583 ±2 
108 3631 499 3590 ++ 
147 3566 + 511 3565 ++ 
170 3593 512 3595 ++ 
216 3554 ± 536 3553 ++ 
262 3630 536 3628 
271 3577 ++2 554 3586 3 
336 3582 ± 555 3569 ++ 
345 3579 + 559 3594 ++ 
366 3580 624 3570 + 
369 3589 + 677 3568 ++ 
379 3596 ++ 681 3591 3 
391 3578 +2 684 3629 
424 3592 ± 695 3581 +3 
I 
- =negative, ±= weakly positive, += positive, ++= strongly positive 
2 Atypical staining with diffuse fluorescence along airways. 
3 High background across tissue prevented assessment. 
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DISCUSSION 
Due to the access to a large portion of the annotated genome sequence of M 
hyopneumoniae, it was possible to design primers to amplify portions of the ORFs of 
interest. Cloning of these PCR products into pCR2.1-TOPO was a strategy based on ease 
and universality. No further modifications had to be made to the PCR fragments to ligate 
them with pCR2.1 and all fragments produced from different ORFs could be ligated with the 
same vector. pCR2.1 also contains a fragment of lacZ which complements the Ml 5 mutation 
allowing blue/white selection in the appropriate host. Cloning within this fragment interrupts 
complementation, making screening for successful clones less of a challenge. Initial cloning 
was expedited by the use of this general-application plasmid. Also, the smaller size of the 
vector as compared to the much larger eukaryotic expression vector was thought to enhance 
the effectiveness of the site-directed mutagenesis steps. 
Plasmid pSTBO78 was chosen for the DNA vaccination studies because of the previous 
experience of this laboratory with its parent plasmid, VRl 020. This vector contains a CVM 
promoter for expression in mammalian hosts followed by tP A sequences that direct expressed 
products to the cell surface. In previous studies, it was found that the tP A sequences gave an 
enhanced immunological response in mice to the cloned sequences over a vector that lacked 
the sequences (Menon and Minion, unpublished). Also, the constructs developed during this 
study will be used in pig vaccine studies so every effort was made to choose the most 
effective vector for those studies. The use of this vector, however, required that cloning be in-
frame with the tP A sequences creating a protein fusion. Thus during primer design, one had to 
take into account the specific gene sequences, the restriction sites added at each end with 
extra bases to enhance restriction enzyme digestion, and the frame of the fragment once it was 
inserted into the vector. In some instances, inserts contained small deletions at one end 
following insertion into pSTB078 moving the sequence out of frame. This required a second 
round of site-directed mutagenesis to bring the cloned fragment into frame. 
The restriction sites used for cloning into pSTB078 were chosen based on several criteria. 
Each ORF was checked for the presence of the more common restriction sites found in the 
multiple cloning site of pSTBO78 and eliminated from consideration if present. There was 
also a preference for 3' overhang cutters and avoidance for .XbaI, due to lack of cutting when 
using methylated DNA. PCR conditions were optimized to produce the correct bands and 
ligation conditions optimized to successfully clone into pSTBO78. The final clone was 
sequenced and examined for any insertions, deletions or other mutations that might inhibit 
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expression. If these were found, further site-directed mutagenesis was employed to restore 
the desired sequence. 
Like most mycoplasmas, M hyopneumoniae recognizes the codon TGA as the codon for 
tryptophan, rather than as a stop codon as it is by other organisms. To express M 
hyopneumoniae ORFs in a eukaryotic system, i.e., a DNA vaccine in an animal host, it was 
necessary to alter this sequence so that full-length proteins would be produced instead of 
truncated products. This was accomplished by site-directed mutagenesis of all in-frame TGA 
codons into TGG by PCR with mutagenic primers. Opal suppressor mutants have been 
described that are partially effective in allowing readthrough of TGA codons during 
translation (83), but these would be ineffective in a mammalian host. Therefore, the offending 
stop codons had to be completely removed, not just suppressed. Only randomly introduced 
mutations during the PCR process could reintroduce premature stop codons. Even though the 
probability for this is low, mutations were verified after mutagenesis and after PCR cloning 
into pSTBO78 to verify and confirm the final clone sequence. 
Immunoblot analysis provided the initial screen for the rabbit antisera. Initial 
immunoblots used a goat anti-rabbit IgG secondary antibody specific to whole rabbit 
antibodies. This conjugate yielded many non-specific bands when used to develop gels 
blotted with the rabbit sera. To correct this problem, it was necessary to blot using a mouse 
secondary antibody specific to the rabbit IgG heavy chain. This increased specificity for 
rabbit antibodies and significantly reduced the non-specific bands. Rabbit sera and secondary 
antibodies were diluted in TS-Tween with 5% mycoplasma-free pig serum to further reduce 
nonspecific bands. The dilution factor of the rabbit sera was also varied to eliminate non-
specific bands. It was found that at high concentrations, blots would show matching bands in 
prebleed and final bleed sera, as well as final bleed-unique bands. At a concentration specific 
to each rabbit, the non-specific bands would fail to develop, leaving the desired unique bands. 
For some of the antisera recognizing fainter bands, it was necessary to increase the 
concentration of the rabbit sera or the amount of M hyopneumoniae antigen for the band to 
develop, which sometimes led to an increase in non-specific binding. This is the case in ORFs 
170, 216, 536, 536 (negative strand), 554, and 681. Some bands remained faint, despite 
increases in concentration, indicating proteins that are expressed at a low level in the 
laboratory grown M hyopneumoniae whole cell antigen used or lack of reactivity of the 
antisera. Antisera that were scored as positive by immunoblot have unique bands in the final 
bleed serum that are either the expected size or smaller, possibly indicating a posttranslational 
modification event. Knowing the size of the desired proteins gave us a tool to discern which 
of the bands were related to our vaccinations. 
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In the immunoblotting results there is a substantial amount of non-specific binding by the 
rabbit antisera as indicated by bands that are present in both the prebleed serum and the final 
bleed serum. The amount of non-specific binding of rabbit antibodies to proteins in the 
proteome of M hyopneumoniae in this study is greater than one would expect for rabbits 
exposed to only one M hyopneumoniae protein by vaccination. Some of the immunoblots 
showed 10-20 non-specific bands, suggesting many of these antibodies existed. One 
explanation is that the non-specific binding was due to the low dilution of rabbit serum used 
in the immunoblot studies. This is shown with ORFs 554,681,624,345, 536, 536 (negative 
strand), 216, 170, and 369 in Figure 4. In these cases, the predicted, unique band on the gel 
was too faint to visualize at higher dilutions of the serum, so it was necessary to react 
immunoblots with more concentrated antiserum. It is possible that the cross-reactive proteins 
in each rabbit sera are antigenically-related to proteins in other bacterial species such as those 
of the normal flora. Not all rabbits would respond in the same fashion to these common 
bacterial antigens, and it would be expected that antibodies to common bacterial antigens 
would be in low concentration since they would be present in normal flora. The need for low 
antibody dilutions and cross-reactivity to common bacterial antigens form a unified 
hypothesis that supports our results. It should not be surprising to find antibody reactivity 
against common bacterial proteins in conventionally-raised rabbits reacting with mycoplasma 
proteins. 
Another explanation is that rabbits had been exposed to another mycoplasma 
antigenically related to M hyopneumoniae resulting in antibodies cross-reactive to M 
hyopneumoniae proteins. The most likely species would be mycoplasmas that have been 
found to infect rabbits such as M fermentans , M arthritidis, and M pulmonis although these 
species are not thought to be antigenically related (73, 94). The rabbitry where the test 
rabbits used in these studies are produced does not screen for mycoplasmas due to the 
expense of such screens. There is no reason to think that these animals were completely free 
from infectious organisms although the animals appeared to be in good health. Mycoplasma 
infections can be clinically silent. 
Many of the blots, like ORFs 262,424, and 511, showed unique bands of the size 
predicted by computation of protein products weight (kDa) based on nucleotide sequence. 
Some of these, such as ORFs 624, 559, and 624 (Figure 4), also showed smaller, unique bands 
in addition to the expected, whole-product band. These bands are believed to be the result of 
two possible outcomes. Post-translational cleavage of the protein product could produce 
several differently sized peptides recognized by the rabbit antibodies. The cleaved fragments 
would show up as smaller bands, sometimes in addition to the full sized protein. Unlike 
38 
monoclonal antibodies, these antisera are polyclonal reacting to epitopes throughout the 
cloned sequence and would thus recognize all parts of the molecule. Alternatively, the 
antisera could be cross-reacting with other mycoplasma proteins. ORFs 624, 559 and 624 are 
members of a large paralog family of membrane transport proteins suggesting that some 
cross-reaction may be occurring. ORF 559 is also a member of that family. Some of the blots, 
such as ORFs 108, 366, and 684, indicate complete cleavage of the full sized protein by the 
fact that the expected full sized band is not present, yet smaller, unique bands appear. Most 
often, these smaller bands had a cleavage pattern that indicated random recognition sites by 
proteases, but in the cases of ORFs 466, 559, 684 the smaller bands had an evenly spaced, 
ladder pattern. ORF 466 is a conserved hypothetical lipoprotein with no repeat regions. The 
banding pattern recognized by this antiserum suggests posttranslational cleavage of the 
protein. ORF 684 is a member of a paralog family of adhesin (P97)-related proteins ( 40, 97). 
This antiserum might also be cross-reacting with other members of that family including P97. 
In one case, ORF 466, an inadequate amount of prebleed serum was collected and the 
supply of serum was exhausted during preliminary studies and was unavailable for this 
study. However, these preliminary screens of rabbit serum gave no indications of any bands 
specific to mycoplasma proteins and blots from this study show a band of the expected size 
and several fragments indicative of size variation or proteolytic cleavage. 
In thirteen of the thirty-four rabbits, no antibodies were raised that bound uniquely with 
proteins from M hyopneumoniae strain 232 grown under laboratory conditions. The final 
bleed bands resolved from these rabbits most often showed many non-specific bands that 
matched the bands in the prebleed. Three possible explanations exist. First, the protein may 
not have been expressed properly in the rabbit. If an unexpected problem arose with the 
pSTBO78 expression clones that caused them not to be expressed properly, the protein 
would never have been present in the rabbit and no antibody would be raised to produce a 
unique band. Second, another possibility is that no appreciable titer of antibody was raised 
by the rabbit in response to the presence of a properly expressed protein. It is not 
uncommon for individuals to lack a significant response to a particular antigen. Only a single 
rabbit was immunized with each DNA construct, and it is not unusual to have nonresponding 
animals. Also, DNA vaccinations do not normally produce high antibody levels in response 
to vaccination. It could be that some antisera have low antibody titers as a result of the 
vaccination scheme independent of protein expression and individual host response. 
Eventually it will be necessary to repeat the vaccinations to eliminate this possibility. 
Finally, M hyopneumoniae has been often reported as a difficult organism to grow under 
laboratory conditions and one whose nature may change in such conditions (80) (107). It is 
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not unlikely that the antigens produced by M hyopneumoniae grown in vitro for this 
experiment was different than that one would find in vivo during an infection. Studies from 
other mycoplasmas indicate that the expression of mycoplasmal proteins is in constant flux, 
with or without environmental affects (102). As such, it is doubtful that all surface proteins 
and lipoproteins would be expressed at the same time. A negative result for these 
imrnunoblots could simply indicate that the protein we have raised antibodies against is not 
expressed in our lab grown M hyopneumoniae. This, of course, does not mean that the same 
strain under other conditions, such as those found in vivo, would express the same set of 
surface proteins. 
To examine this last possibility, the rabbit antisera were also used in imrnunofluorescence 
tests of infected swine respiratory tissues to determine if the antigens were expressed in vivo. 
Tissues were collected at 28 days following experimental infection with M hyopneumoniae 
strain 232. These results were subjectively scored based on fluorescence intensities. The 
prebleed sera were first screened by limiting dilutions to determine the minimum dilution 
needed to screen the final bleed sera. All sera were screened on at least three different tissues 
representing different pigs at the final dilution. Positive results indicate that the gene was 
expressed in vivo during disease. 
A comparison of the results of the imrnunoblotting and imrnunofluorescence studies 
shows distinct differences. The two sets of results do not correlate well, having only 
seventeen of the thirty-four ORFs that give the same result, fifteen positive and three 
negative. The other seventeen ORFs tested showed differing results between the two 
imrnunoassays. Ten were found positive during imrnunoblotting only. Seven were found 
positive during imrnunofluorescence only. It was not expected that the two results would 
correlate perfectly, however. One assay (immunoblotting) used in vitro grown antigen oflow-
passage M hyopneumoniae strain 232. In contrast, the immunofluorescence assay 
represented in vivo grown antigen present in infected tissues, organisms that had colonized 
the lung and grew in vivo over a 28-day period. Not only are the growth environments 
different, it is possible that a selection process had occurred at the point of colonization and 
that selective pressure during the 28 days resulted in an antigenically-distinct popoulation 
significantly different from the infecting population. This has been shown for other 
mycoplasma species (19, 35). 
Another issue that would affect the outcomes of these experiments would be the effect 
the eukaryotic expression machinery might have on mycoplasma protein length, charge, or 
processing, and how that might affect the immune response. We did not examine the antisera 
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directly for reactivity against recombinant or purified proteins so it was not possible to 
measure antibody reactivity independently. 
The location of final protein products in M hyopneumoniae cell could also play a role in 
the difference between the two sets ofresults. For immunoblotting, M hyopneumoniae total 
cell antigens were denatured and resolved by SDS-PAGE. In the immunofluorescence study, 
the only proteins available for antibody binding were those on the exterior cell surface. 
Proteins that were located intracellularly would not normally be exposed to antibody and 
those released into the extracellular space would be washed away during the tissue 
preparation. This could explain the differences between the two sets of results. 
Proteins found negative still warrant further investigation due to the chance that they 
could be expressed in vivo, but below the threshold of detection by immunofluorescence. 
Proteins found positive in this study represent antibodies successfully raised against the 
desired protein product. In summary, these results can be used to support the hypothesis 
that the DNA vaccine constructs used to immunize rabbits are successful in eliciting a 
humoral immune response against the M hyopneumoniae protein encoded by the vaccine. 
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CONCLUSIONS 
This study represents one of the first data mining activities of the M hyopneumoniae 
genome sequence. It is also a first step in developing reagents needed to study the surface 
architecture of M hyopneumoniae. An understanding of the mycoplasma surface is critical to 
solving the pathogenic process. This study also will have an immediate impact on a long-term 
goal of this laboratory, to develop improved vaccines. This requires substantial information 
on the protective efficacy of individual antigens obtained though animal challenge 
experiments, but these studies are an important first step toward this goal. 
The two assays performed with the antisera represent both in vitro and in vivo grown 
antigens; immunoblotting used in vitro grown antigen and immunofluorescence used in vivo 
grown organisms. These tests were chosen with this in mind. Variability in the results 
between the two assays could indicate expression differences in the two growth 
environments. This will require additional experimentation to confirm. 
Lipoproteins are the major proteins of the mycoplasma surface. There have been no 
comprehensive studies of the lipoproteins of M hyopneumoniae primarily because of the 
difficulty in growing the organism. Tools and reagents are also lacking. Monoclonal antibodies 
have been produced against M hyopneumoniae proteins, but they are not well characterized 
as to the gene product recognized. This study has produced protein-specific antibodies that 
can be used for further study into the nature of these proteins, their expression and possible 
posttranslational modification events. These reagents will allow a variety of future studies 
including growth-dependent variation in expression and variation in field isolates, all of which 
will have direct relevance on the construction of improved subunit vaccines. 
DNA vaccines have the potential to substantially improve protection against disease. 
They are limited, however, in that they require knowledge of the critical antigens needed for 
protection. This is difficult to determine with bacterial pathogens because of the plethora of 
antigens and the ability of the organism to rapidly regulate the expression of those antigens. 
Mycoplasmas differ in that they do not regulate their antigens to the same extent as other 
bacteria. Also, the number of potential protective antigens is limited because of the small 
genome size. Now that the complete genome sequence of M hyopneumoniae is known, it is 
possible to methodically test each possible antigen for its protective potential in a vaccine 
format. The studies completed here are a first step in that direction. Plasmid constructs used 
for rabbit vaccinations will also be used in pigs in a vaccine challenge model. 
This investigation used both immunoblotting and Immunofluorescence to validate the 
ability of DNA vaccines to elicit humoral responses to M hyopneumoniae antigens in an 
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animal model. The data showed that this is a system applicable to the actual production of 
antibodies, limited only by our choice of ORF and levels of detection of antibody binding in 
the laboratory. We were able to detect, to some level, the binding of antibodies from thirty-
one of the thirty-four immunized rabbits with M hyopneumoniae proteins. This is an 
encouraging result for future use of these vaccines in increasing resistance to M. 
hyopneumoniae in swine. Further investigation into the actual effect of these vaccines on 
swine challenged with M hyopneumoniae would be the true test of the efficacy of the 
constructs in increasing resistance to the disease. Studies are currently underway by Drs. F. 
Chris Minion and Eileen Thacker at Iowa State University and by the Merial Company to 
this end. 
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